Free Trial

Trevi Therapeutics (TRVI) Insider Trading & Ownership

Trevi Therapeutics logo
$4.06 +0.01 (+0.25%)
(As of 05:45 PM ET)

Trevi Therapeutics (NASDAQ:TRVI) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
24.37%
Number Of
Insiders Buying
(Last 12 Months)
0
Number Of
Insiders Selling
(Last 12 Months)
4
Amount Of
Insider Selling
(Last 12 Months)
$349,116.96
Get TRVI Insider Trade Alerts

Want to know when executives and insiders are buying or selling Trevi Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

TRVI Insider Buying and Selling by Quarter

Trevi Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/9/2024Jennifer L GoodCEOSell1,840$3.04$5,593.60  
9/6/2024Jennifer L GoodCEOSell4,219$3.03$12,783.57  
9/4/2024Jennifer L GoodCEOSell10,981$3.02$33,162.62  
8/27/2024David P MeekerDirectorSell4,555$2.93$13,346.15  
8/16/2024Thomas SciasciaInsiderSell18,660$2.76$51,501.60  
8/14/2024Thomas SciasciaInsiderSell100$2.75$275.00  
5/29/2024Thomas SciasciaInsiderSell53,368$2.55$136,088.40  
5/22/2024Lisa DelfiniCFOSell4,350$2.64$11,484.00  
5/20/2024Jennifer L GoodCEOSell25,037$2.86$71,605.82  
5/10/2024Jennifer L GoodCEOSell4,578$2.90$13,276.20  
(Data available from 1/1/2013 forward)

TRVI Insider Trading Activity - Frequently Asked Questions

The list of insiders at Trevi Therapeutics includes David P Meeker, Jennifer L Good, Lisa Delfini, Paul Edward Walker, Thomas Sciascia, and Tpg Gp A, Llc. Learn more on insiders at TRVI.

24.37% of Trevi Therapeutics stock is owned by insiders. Learn more on TRVI's insider holdings.

The following insiders have sold TRVI shares in the last 24 months: David P Meeker ($13,346.15), Jennifer L Good ($136,421.81), Lisa Delfini ($43,329.30), and Thomas Sciascia ($187,865.00).

Insiders have sold a total of 141,369 Trevi Therapeutics shares in the last 24 months for a total of $380,962.26 sold.

Trevi Therapeutics Key Executives

  • Ms. Jennifer L. Good (Age 59)
    Co-Founder, CEO, President & Director
    Compensation: $781.85k
    3 recent trades
  • Dr. Thomas R. Sciascia M.D. (Age 71)
    Co-Founder & Chief Science Officer
    Compensation: $530.48k
  • Dr. David J. Clark A.F.P.M. (Age 59)
    M.D., M.R.C.P., Chief Medical Officer
    Compensation: $325.39k
  • Ms. Lisa Delfini (Age 54)
    Chief Financial Officer
  • Mr. Christopher Galletta (Age 46)
    Controller & Chief Accounting Officer
  • Katie McManus
    Communications Manager
  • Mr. Farrell Simon Pharm.D.
    Chief Commercial Officer
  • Ms. Danine Summers (Age 66)
    Vice President of Medical Affairs


This page (NASDAQ:TRVI) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners